Viveve CEO Scott Durbin Named One of the Top 50 Health Tech Leaders of 2022 by Health Tech Report

Durbin Recognized for Second Consecutive Year for Leading the Development of Viveve’s Innovative Technology for the Treatment of Female Stress Urinary Incontinence

ENGLEWOOD, CO/ACCESSWIRE/May 17, 2022/ Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that Scott Durbin, the company’s CEO, has been named by Healthcare Technology Report as one of the Top 50 Health Technology CEOs of 2022. Mr. Durbin was also named one of the Top 50 Health Technology CEOs of 2021.

The Health Technology Report annually recognizes accomplished senior health technology executives who have driven their company to advance innovative healthcare solutions and improve patient care. The companies represented on the list are active in various areas of health technology, including software platforms, medical devices and therapeutics. While the 2022 winners come from diverse backgrounds and have widely varying professional backgrounds, they have consistently led their respective companies to new levels of dynamism and success through their leadership, business acumen and commitment to their employees and their clients.

“It is an honor to be named one of the Healthcare Technology Report’s Top 50 Healthcare Technology CEOs for a second year and to be in the company of the other recipients of this prestigious recognition. I attribute this recognition to the talented employees and dedicated people of Viveve who it is a privilege to serve as CEO,” said Durbin. “Our entire organization is united in the belief that our innovative dual-energy technology has the potential to meet the significant need for a non-invasive, safe and long-lasting treatment for stress urinary incontinence or SUI in women. SUI is a condition that affects the daily activities and quality of life of millions of women. Our primary goal is to successfully complete our pivotal US PURSUIT clinical trial, achieve positive results, and obtain a new SUI indication in the United States,” concluded Mr. Durbin.

About Viveve
Viveve Medical, Inc. is a medical technology company focused on women’s intimate health. Viveve is committed to providing new solutions to improve the general well-being and quality of life of women. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency technology to evenly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve® System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or enhancement of sexual function indications in 50 countries.

Viveve continues to advance its clinical development program in stress urinary incontinence (SUI). Viveve has received FDA approval for its investigational device exemption (IDE) application to conduct the multicenter, randomized, double-blind, simulation-controlled PURSUIT trial for the improvement of SUI in women in July 2020 and FDA approval of its requested amendments to the IDE protocol in December 2020. Trial initiation was reported in January 2021 and subject enrollment completion was announced on December 14, 2021. First results are expected in late 2022. If positive, PURSUIT trial results may support new SUI indication in US

For more information, visit the Viveve website at

Safe Harbor Statement
All statements in this press release that are not based on historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, implied statements and express statements regarding Viveve Medical, Inc.’s plans, timelines, or outcome assumptions for the PURSUIT trial. Although management has based the forward-looking statements included in this press release on its current expectations, the information on which these expectations were based may change. These forward-looking statements are based on a number of assumptions about future events and are subject to a number of risks, uncertainties and other factors, many of which are beyond our control, which could cause actual results differ materially from those statements. These risks, uncertainties and other factors include, but are not limited to, the timing, progress and results of our clinical trials, fluctuating global economic conditions, the impact of the novel coronavirus known as COVID-19 on our clinical development and our regulatory review. and authorizations and on the manufacture, placement and patient use of our Viveve systems, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors which are detailed in our periodic and current reports available for review at Additionally, we operate in a highly competitive and rapidly changing environment where new and unforeseen risks may arise. Accordingly, investors should not rely on forward-looking statements as a prediction of actual results. We disclaim any intention and undertake no obligation to update or revise any forward-looking statements to reflect events or circumstances which occur subsequently or become known to us, except as required by law.

Viveve is a registered trademark of Viveve, Inc.

Investor Relations contacts:
Amato and Partners, LLC
Investor Relations Advisor
[email protected]

Media contact:
Bill Berry
Berry & Company Public Relations
(212) 253-8881
[email protected]

THE SOURCE: Viveve Medical, Inc.

See the source version on

Comments are closed.